Curanex Pharmaceuticals Inc
CURX
$0.44
$0.037.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 131.34% | 156.85% | 251.92% | 1,351.55% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 425.35% | 156.85% | 251.92% | 1,351.55% | -- |
| Operating Income | -425.35% | -156.85% | -251.92% | -1,351.55% | -- |
| Income Before Tax | -464.70% | -210.94% | -326.40% | -1,727.98% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -464.70% | -210.94% | -326.40% | -1,727.98% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -464.70% | -210.94% | -326.40% | -1,727.98% | -- |
| EBIT | -425.35% | -156.85% | -251.92% | -1,351.55% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 75.76% | 70.03% | 57.70% | -509.97% | -- |
| Normalized Basic EPS | 77.18% | 71.81% | 59.64% | -501.50% | -- |
| EPS Diluted | 75.76% | 70.03% | 57.70% | -509.97% | -- |
| Normalized Diluted EPS | 77.18% | 71.81% | 59.64% | -501.50% | -- |
| Average Basic Shares Outstanding | 1,527.97% | 1,673.30% | 2,103.27% | 1,128.27% | -- |
| Average Diluted Shares Outstanding | 1,527.97% | 1,673.30% | 2,103.27% | 1,128.27% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |